A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 [raltegravir] Versus KALETRA [lopinavir/ritonavir] in HIV-Infected Patients Switched From a Stable KALETRA-Based Regimen - Study B.

Trial Profile

A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 [raltegravir] Versus KALETRA [lopinavir/ritonavir] in HIV-Infected Patients Switched From a Stable KALETRA-Based Regimen - Study B.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Antiretrovirals; Lopinavir/ritonavir; Raltegravir
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SWITCHMRK-2
  • Most Recent Events

    • 13 Jan 2010 Results were published in The Lancet.
    • 13 Feb 2009 Planned end date changed from 1 May 2011 to 1 Jun 2009, as reported by ClinicalTrials.gov.
    • 10 Feb 2009 Status changed from active, no longer recruiting to discontinued according to a media release from http://www.merck.com.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top